Arnhold LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Arnhold LLC has acquired a new stake in Regeneron Pharmaceuticals, purchasing 6,228 shares valued at approximately $3.27 million in the second quarter.
• Regeneron's latest quarterly earnings report revealed an EPS of $12.89, exceeding analyst estimates by $4.46, with revenue reaching $3.68 billion.
• The firm declared a quarterly dividend of $0.88 per share, representing an annualized dividend yield of 0.6% and a payout ratio of 8.87%.

Arnhold LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 6,228 shares of the biopharmaceutical company's stock, valued at approximately $3,270,000.

Several other institutional investors have also added to or reduced their stakes in REGN. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management lifted its stake in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 21 shares during the last quarter. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Saudi Central Bank bought a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Finally, Colonial Trust Advisors bought a new stake in Regeneron Pharmaceuticals in the first quarter worth about $32,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ REGN opened at $578.05 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,002.69. The stock has a market capitalization of $61.27 billion, a P/E ratio of 14.57, a PEG ratio of 1.77 and a beta of 0.31. The stock's fifty day moving average is $574.64 and its 200 day moving average is $562.89.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the business earned $11.56 earnings per share. Regeneron Pharmaceuticals's revenue was up 3.6% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday, September 2nd. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $817.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.